长华化学 reported revenue of ¥1.60B for the period ended 2026-06-30, +29.8% year on year. Net income was ¥-0.04B, a -2.6% net margin on a 3.2% gross margin. The largest revenue line is POP at 62% of the total. Free cash flow for the period was ¥-0.16B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.60B | +29.8% |
| Gross profit | ¥0.05B | — |
| Operating income | ¥-0.06B | — |
| Net income | ¥-0.04B | -199.8% |
| Gross margin | 3.2% | Net margin -2.6% |
| Revenue Q/Q | +37.9% | — |
| Segment | Revenue | Share |
|---|---|---|
| POP | ¥1.00B | 62.4% |
| 软泡用PPG | ¥0.44B | 27.3% |
| CASE用聚醚及特种聚醚 | ¥0.15B | 9.4% |
| 其他(补充) | ¥0.02B | 0.9% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥1.55B | 96.8% |
| R&D | ¥0.01B | 0.6% |
| SG&A | ¥0.05B | 3.4% |
| Tax & other | ¥-0.02B | -1.2% |
| Item | Amount |
|---|---|
| Total assets | ¥3.63B |
| Total liabilities | ¥2.02B |
| Shareholders' equity | ¥1.61B |
| Equity / assets | 44.4% |
| Operating cash flow | ¥0.00B |
| Capital expenditure | ¥0.16B |
| Free cash flow | ¥-0.16B |
| Cash conversion (OCF / net income) | 165% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
舜禹股份 ・ 万邦医药 ・ 上大股份 ・ 儒竞科技 ・ 国际复材 ・ 多浦乐 ・ 福赛科技 ・ 春光集团 ・ 威马农机 ・ 浙江华远 ・ 星宸科技 ・ 骏鼎达
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies